Drug maker BioSante Pharmaceuticals Inc. (NASDAQ: BPAX) has released the results of a Phase Ib study of its pancreatic cancer vaccine GVAX indicating that, when used in combination with another drug, patients survive longer. The drug combination “increased the median survival of pancreatic cancer patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma survival rate” by 60%, from 3.3 months to 5.5 months. The study also showed a jump in one-year survival from 7% to 27%.
In the pre-market this morning, BioSante shares are up about 25% at $0.86.
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
